Cystic  ||| S:0 E:7 ||| NNP
Fibrosis  ||| S:7 E:16 ||| NNP
Foundation  ||| S:16 E:27 ||| NNP
practice  ||| S:27 E:36 ||| NN
guidelines  ||| S:36 E:47 ||| NNS
for  ||| S:47 E:51 ||| IN
the  ||| S:51 E:55 ||| DT
management  ||| S:55 E:66 ||| NN
of  ||| S:66 E:69 ||| IN
infants  ||| S:69 E:77 ||| NNS
with  ||| S:77 E:82 ||| IN
cystic  ||| S:82 E:89 ||| FW
fibrosis  ||| S:89 E:98 ||| FW
transmembrane  ||| S:98 E:112 ||| FW
conductance  ||| S:112 E:124 ||| FW
regulator-related  ||| S:124 E:142 ||| FW
metabolic  ||| S:142 E:152 ||| FW
syndrome  ||| S:152 E:161 ||| NN
during  ||| S:161 E:168 ||| IN
the  ||| S:168 E:172 ||| DT
first  ||| S:172 E:178 ||| JJ
two  ||| S:178 E:182 ||| CD
years  ||| S:182 E:188 ||| NNS
of  ||| S:188 E:191 ||| IN
life  ||| S:191 E:196 ||| NN
and  ||| S:196 E:200 ||| CC
beyond  ||| S:200 E:207 ||| IN
Through  ||| S:207 E:215 ||| IN
early  ||| S:215 E:221 ||| JJ
detection ||| S:221 E:230 ||| NN
,  ||| S:230 E:232 ||| ,
newborn  ||| S:232 E:240 ||| JJ
screening  ||| S:240 E:250 ||| NN
( ||| S:250 E:251 ||| -LRB-
NBS ||| S:251 E:254 ||| NNP
) ||| S:254 E:255 ||| -RRB-
( ||| S:255 E:256 ||| -LRB-
1 ||| S:256 E:257 ||| LS
)  ||| S:257 E:259 ||| -RRB-
for  ||| S:259 E:263 ||| IN
cystic  ||| S:263 E:270 ||| JJ
fibrosis  ||| S:270 E:279 ||| NNS
( ||| S:279 E:280 ||| -LRB-
CF ||| S:280 E:282 ||| NNP
)  ||| S:282 E:284 ||| -RRB-
offers  ||| S:284 E:291 ||| VBZ
the  ||| S:291 E:295 ||| DT
opportunity  ||| S:295 E:307 ||| NN
for  ||| S:307 E:311 ||| IN
early  ||| S:311 E:317 ||| JJ
intervention  ||| S:317 E:330 ||| NN
and  ||| S:330 E:334 ||| CC
improved  ||| S:334 E:343 ||| JJ
outcomes ||| S:343 E:351 ||| NNS
.  ||| S:351 E:353 ||| .
NBS  ||| S:353 E:357 ||| NNP
programs  ||| S:357 E:366 ||| NNS
screen  ||| S:366 E:373 ||| NN
for  ||| S:373 E:377 ||| IN
hypertrypsinogenemia ||| S:377 E:397 ||| NN
,  ||| S:397 E:399 ||| ,
and  ||| S:399 E:403 ||| CC
most  ||| S:403 E:408 ||| RBS
also  ||| S:408 E:413 ||| RB
identify  ||| S:413 E:422 ||| VB
mutations  ||| S:422 E:432 ||| VBN
in  ||| S:432 E:435 ||| IN
the  ||| S:435 E:439 ||| DT
CF  ||| S:439 E:442 ||| NNP
transmembrane  ||| S:442 E:456 ||| FW
conductance  ||| S:456 E:468 ||| FW
regulator  ||| S:468 E:478 ||| FW
( ||| S:478 E:479 ||| -LRB-
CFTR ||| S:479 E:483 ||| NNP
)  ||| S:483 E:485 ||| -RRB-
gene ||| S:485 E:489 ||| NN
.  ||| S:489 E:491 ||| .
Individuals  ||| S:491 E:503 ||| NNS
identified  ||| S:503 E:514 ||| VBN
by  ||| S:514 E:517 ||| IN
NBS  ||| S:517 E:521 ||| NNP
are  ||| S:521 E:525 ||| VBP
diagnosed  ||| S:525 E:535 ||| VBN
with  ||| S:535 E:540 ||| IN
CF  ||| S:540 E:543 ||| NNP
if  ||| S:543 E:546 ||| IN
they  ||| S:546 E:551 ||| PRP
have  ||| S:551 E:556 ||| VBP
an  ||| S:556 E:559 ||| DT
elevated  ||| S:559 E:568 ||| JJ
sweat  ||| S:568 E:574 ||| NN
chloride  ||| S:574 E:583 ||| NN
level  ||| S:583 E:589 ||| NN
or  ||| S:589 E:592 ||| CC
if  ||| S:592 E:595 ||| IN
they  ||| S:595 E:600 ||| PRP
have  ||| S:600 E:605 ||| VBP
inherited  ||| S:605 E:615 ||| VBN
2  ||| S:615 E:617 ||| CD
disease-causing  ||| S:617 E:633 ||| JJ
mutations  ||| S:633 E:643 ||| NNS
in  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
CFTR  ||| S:650 E:655 ||| NNP
gene ||| S:655 E:659 ||| NN
.  ||| S:659 E:661 ||| .
Mutations  ||| S:661 E:671 ||| NNS
in  ||| S:671 E:674 ||| IN
the  ||| S:674 E:678 ||| DT
CFTR  ||| S:678 E:683 ||| NNP
gene  ||| S:683 E:688 ||| NN
can  ||| S:688 E:692 ||| MD
cause  ||| S:692 E:698 ||| VB
CF ||| S:698 E:700 ||| NNP
,  ||| S:700 E:702 ||| ,
but  ||| S:702 E:706 ||| CC
not  ||| S:706 E:710 ||| RB
all  ||| S:710 E:714 ||| DT
CFTR  ||| S:714 E:719 ||| NNP
mutations  ||| S:719 E:729 ||| NNS
are  ||| S:729 E:733 ||| VBP
disease-causing ||| S:733 E:748 ||| JJ
.  ||| S:748 E:750 ||| .
The  ||| S:750 E:754 ||| DT
term  ||| S:754 E:759 ||| NN
CFTR-related  ||| S:759 E:772 ||| JJ
metabolic  ||| S:772 E:782 ||| JJ
syndrome  ||| S:782 E:791 ||| NN
( ||| S:791 E:792 ||| -LRB-
CRMS ||| S:792 E:796 ||| NNP
)  ||| S:796 E:798 ||| -RRB-
is  ||| S:798 E:801 ||| VBZ
proposed  ||| S:801 E:810 ||| VBN
to  ||| S:810 E:813 ||| TO
describe  ||| S:813 E:822 ||| VB
infants  ||| S:822 E:830 ||| NNS
identified  ||| S:830 E:841 ||| VBN
by  ||| S:841 E:844 ||| IN
hypertrypsinogenemia  ||| S:844 E:865 ||| NN
on  ||| S:865 E:868 ||| IN
NBS  ||| S:868 E:872 ||| NNP
who  ||| S:872 E:876 ||| WP
have  ||| S:876 E:881 ||| VBP
sweat  ||| S:881 E:887 ||| JJ
chloride  ||| S:887 E:896 ||| NN
values  ||| S:896 E:903 ||| VBZ
< ||| S:903 E:904 ||| SYM
60  ||| S:904 E:907 ||| CD
mmol ||| S:907 E:911 ||| CD
/ ||| S:911 E:912 ||| CD
L  ||| S:912 E:914 ||| NNP
and  ||| S:914 E:918 ||| CC
up  ||| S:918 E:921 ||| RB
to  ||| S:921 E:924 ||| TO
2  ||| S:924 E:926 ||| CD
CFTR  ||| S:926 E:931 ||| NN
mutations ||| S:931 E:940 ||| NNS
,  ||| S:940 E:942 ||| ,
at  ||| S:942 E:945 ||| IN
least  ||| S:945 E:951 ||| JJS
1  ||| S:951 E:953 ||| CD
of  ||| S:953 E:956 ||| IN
which  ||| S:956 E:962 ||| WDT
is  ||| S:962 E:965 ||| VBZ
not  ||| S:965 E:969 ||| RB
clearly  ||| S:969 E:977 ||| RB
categorized  ||| S:977 E:989 ||| VBN
as  ||| S:989 E:992 ||| IN
a  ||| S:992 E:994 ||| DT
CF-causing  ||| S:994 E:1005 ||| JJ
mutation ||| S:1005 E:1013 ||| NN
,  ||| S:1013 E:1015 ||| ,
thus  ||| S:1015 E:1020 ||| RB
they  ||| S:1020 E:1025 ||| PRP
do  ||| S:1025 E:1028 ||| VBP
not  ||| S:1028 E:1032 ||| RB
meet  ||| S:1032 E:1037 ||| VB
CF  ||| S:1037 E:1040 ||| NNP
Foundation  ||| S:1040 E:1051 ||| NNP
guidelines  ||| S:1051 E:1062 ||| NNS
for  ||| S:1062 E:1066 ||| IN
the  ||| S:1066 E:1070 ||| DT
diagnosis  ||| S:1070 E:1080 ||| NN
of  ||| S:1080 E:1083 ||| IN
CF ||| S:1083 E:1085 ||| NNP
.  ||| S:1085 E:1087 ||| .
With  ||| S:1087 E:1092 ||| IN
what  ||| S:1092 E:1097 ||| WP
is  ||| S:1097 E:1100 ||| VBZ
now  ||| S:1100 E:1104 ||| RB
near-universal  ||| S:1104 E:1119 ||| JJ
CF  ||| S:1119 E:1122 ||| NNP
NBS  ||| S:1122 E:1126 ||| NNP
in  ||| S:1126 E:1129 ||| IN
the  ||| S:1129 E:1133 ||| DT
United  ||| S:1133 E:1140 ||| NNP
States ||| S:1140 E:1146 ||| NNPS
,  ||| S:1146 E:1148 ||| ,
an  ||| S:1148 E:1151 ||| DT
increasing  ||| S:1151 E:1162 ||| JJ
number  ||| S:1162 E:1169 ||| NN
of  ||| S:1169 E:1172 ||| IN
infants  ||| S:1172 E:1180 ||| NNS
with  ||| S:1180 E:1185 ||| IN
CRMS  ||| S:1185 E:1190 ||| NNP
are  ||| S:1190 E:1194 ||| VBP
being  ||| S:1194 E:1200 ||| VBG
identified ||| S:1200 E:1210 ||| VBN
.  ||| S:1210 E:1212 ||| .
Given  ||| S:1212 E:1218 ||| VBN
our  ||| S:1218 E:1222 ||| PRP$
inadequate  ||| S:1222 E:1233 ||| JJ
knowledge  ||| S:1233 E:1243 ||| NN
of  ||| S:1243 E:1246 ||| IN
the  ||| S:1246 E:1250 ||| DT
natural  ||| S:1250 E:1258 ||| JJ
history  ||| S:1258 E:1266 ||| NN
of  ||| S:1266 E:1269 ||| IN
CRMS ||| S:1269 E:1273 ||| NNP
,  ||| S:1273 E:1275 ||| ,
standards  ||| S:1275 E:1285 ||| NNS
for  ||| S:1285 E:1289 ||| IN
diagnosis ||| S:1289 E:1298 ||| NN
,  ||| S:1298 E:1300 ||| ,
monitoring ||| S:1300 E:1310 ||| NN
,  ||| S:1310 E:1312 ||| ,
and  ||| S:1312 E:1316 ||| CC
treatment  ||| S:1316 E:1326 ||| NN
are  ||| S:1326 E:1330 ||| VBP
absent ||| S:1330 E:1336 ||| VBN
.  ||| S:1336 E:1338 ||| .
This  ||| S:1338 E:1343 ||| DT
document  ||| S:1343 E:1352 ||| NN
aims  ||| S:1352 E:1357 ||| VBZ
to  ||| S:1357 E:1360 ||| TO
help  ||| S:1360 E:1365 ||| VB
guide  ||| S:1365 E:1371 ||| VB
the  ||| S:1371 E:1375 ||| DT
monitoring  ||| S:1375 E:1386 ||| NN
and  ||| S:1386 E:1390 ||| CC
care  ||| S:1390 E:1395 ||| NN
of  ||| S:1395 E:1398 ||| IN
individuals  ||| S:1398 E:1410 ||| NNS
with  ||| S:1410 E:1415 ||| IN
CRMS  ||| S:1415 E:1420 ||| NNP
while  ||| S:1420 E:1426 ||| IN
our  ||| S:1426 E:1430 ||| PRP$
knowledge  ||| S:1430 E:1440 ||| NN
base  ||| S:1440 E:1445 ||| NN
on  ||| S:1445 E:1448 ||| IN
appropriate  ||| S:1448 E:1460 ||| JJ
management  ||| S:1460 E:1471 ||| NN
evolves ||| S:1471 E:1478 ||| NN
.  ||| S:1478 E:1480 ||| .
